FDA clears IND for Sagimet's denifanstat Phase 3 acne trial

Sagimet Biosciences Inc.

FDA issued 'Study May Proceed' letter for Phase 3 trial of denifanstat in moderate to severe acne.
Denifanstat is a fatty acid synthase inhibitor; trial cleared on August 13, 2026.
Sagimet announced the IND clearance, enabling initiation of the Phase 3 study.
No financial terms or trial design details disclosed in the filing.

Featured in Daily 8-K Digest

Selected #6 for 2026-08-13. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.